Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,130.00
(
0.48%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.49
(
-1.16%
)
Bitcoin
74,527.31
(
0.79%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: pcrutch post# 114845

Friday, 01/13/2012 7:21:04 AM

Friday, January 13, 2012 7:21:04 AM

Post# of 257253
Barron’s compliments itself on its great MNTA call from Feb 2011 (LOL):

http://online.barrons.com/article/SB50001424052748704284404577157213125724728.html

Generic-drug maker Momenta Pharmaceuticals (MNTA) jumped more than 31% after we published our story in February, compared to a 9% decline by the relevant benchmark.

In truth, Barron’s Feb 2011 article on MNTA was moronic (as noted in #msg-59968048).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today